918²«ÌìÌÃ

½Ó´ý»á¼û918²«ÌìÌùٷ½ÍøÕ¾£¡

ÎÄÏ××ÊÁÏ

ÁªÏµ918²«ÌìÌÃ

918²«ÌìÌÃ

µç»°£º0570£­8788056

´«Õ棺0570£­8788381

ÓÊÏ䣺zjgykp@163.com

µØµã£ºÕã½­Ê¡áéÖÝÊж«¸Û¾­¼Ã¿ª·¢Çø

¶«¸Û4·2ºÅ

ÄúËùÔÚµÄÄ¿½ñλÖãºÊ×Ò³ > ÎÄÏ××ÊÁÏ > ÅÅǦÀàÎÄÏ×
  • С·Ö×Ó¸ÌéÙ¹û½º×÷ΪһÖÖÓÐЧǦòüºÏ¼Á¹ØÓÚǦÖж¾»¼¶ùµÄ×÷ÓÃ
  • Ðû²¼Ê±¼ä£º 2019/4/12¡¡µã»÷´ÎÊý£º3330¡¡
  •  

    С·Ö×Ó¸ÌéÙ¹û½º×÷ΪһÖÖÓÐЧǦòüºÏ¼Á¹ØÓÚǦÖж¾»¼¶ùµÄ×÷ÓÃ

    ¡¶Ìæ´úÁÆ·¨¡· £¬2008Äê7Ô£¯8Ô¿¯,14-4

    ÕÔÕýÑÔ, MD; ÁºÁ¢, MD; ·¶ÏþÇå, MD; ÓàÖÓ»ª, PhD; Arland T. Hotchkiss, PhD; Barry J. Wilk, MA; Isaac Eliaz, MD, MS, LAc

    Åä¾°• Ǧ¶¾ÐÔÊÇÒ»¸öÒýÆðÈ«ÇòÁ¬Ðø¹Ø×¢µÄ½¡¿µÎÊÌâ £¬¶øº¢×ÓÊÇ×îÈÝÒ×Êܵ½Ç¦Ì»Â¶µÄºã¾ÃÓ°Ïì £¬ËûÃÇÕýÆÈÇеØÐèÒªÒ»¸öÄþ¾²¡¢ÓÐЧµÄÖؽðÊôòüºÏ¼ÁÈ¥×ÊÖúËûÃǽâ¾öÿÌìÃæÁÙµÄÖؽðÊôºÍǦ̻¶´øÀ´µÄÌôÕ½¡£

    Ä¿µÄ• ½øÐиÃÁÙ´²Ñо¿ £¬ÒÔÈ·¶¨¿Ú·þС·Ö×Ó¸ÌéÙ¹û½º£¨MCP£©ÊÇ·ñÄÜÓÐЧµØ½µµÍ5µ½12Ëê¶ùͯѪҺÖеÄǦ¶¾ÐÔ¡£

    ÒªÁì• ÒÔʯī¯ԭ×ÓÎüÊÕ¹âÆ×·¨£¨Ê¯Ä«Â¯£© £¬¶ÔѪÇåˮƽ´óÓÚ20ug/dL £¬ÇÒÊÔÑéÇ°Èý¸öÔÂûÓнÓÊܹýÈκÎÐÎʽµÄòüºÏ»òÒ©ÎïÖÎÁƵÄסԺ¶ùͯ £¬Ã¿ÈÕ·ÖÈý´Î·þÓù²15gMCP¡£Í¨¹ýʯī¯ԭ×ÓÎüÊÕ¹âÆ×·¨ÆÊÎö £¬»®·ÖÔÚµÚ0Ìì¡¢14Ìì¡¢21Ìì¡¢28ÌìÊÕÂÞѪÇåºÍ24СʱÄÚÄòÒº¡£

    ½á¹û• Ñо¿ÏÔʾѪÇåÖÐǦº¬Á¿¼±¾çϽµ£¨(P=.0016; 161% ƽ¾ù±ä¸ï)  £¬24СʱÄòÒºÖÐǦº¬Á¿¼±¾çÉÏÉý£¨P=.0007; 132%ƽ¾ù±ä¸ï£©¡£

    ½áÂÛ• κÍÄþ¾²µÄÖؽðÊôòüºÏÎïÊǺÜÊÇÐèÒªµÄ £¬ÌرðÊǶԸßÇé¿öºã¾Ã̻¶Ïµĺ¢×Ó¡£Õâ´Î¿ª¶ËÊÔÑéµÄÏÔÖø½á¹ûºÍδÊӲ쵽µÄ²»Á¼·´Ó¦¼°Ö®Ç°µÄ¹ØÓÚMCP¶Ô³ÉÈËÄþ¾²ÓÐЧµÄ±¨µÀ±êÃ÷MCP¿ÉÒÔ×÷ΪÖؽðÊôòüºÏÎï¡£½øÒ»²½Ñо¿À´È·¶¨MCPµÄÀûÒæÊǺÏÀíµÄ¡£(Altern Ther Health Med. 2008;14(4):34-38.£©

     

    ÕÔÕýÑÔ¡¢ÁºÁ¢ £¬Ò½Ñ§²©Ê¿ £¬Öйúº¼ÖÝÕã½­´óѧҽѧԺ¶ùͯҽԺҩѧԺµÄ½ÌÊÚ¡£·¶ÏþÇå £¬Ò½Ñ§²©Ê¿ £¬¼ÓÀû¸£ÄáÑǾɽðɽʥÌØÀ³¹ú¼Ê¹«Ë¾×ܲÃ&Ê×ϯҽÁƹ١£ÓàÖÓ»ª £¬²©Ê¿ £¬Ê¥ÌØÀ³¸±×ܲÃ&Ñо¿Ô±¡£Arland T.Hotchkiss £¬²©Ê¿ £¬±öϦ·¨ÄáÑÇεÂĦ¶ûÃÀ¹úÅ©Òµ²¿Å©ÒµÑо¿¾Ö¶«²¿µØÇøÑо¿ÖÐÐÄÊ×ϯ¿Æѧ¼Ò¡£Barry J. Wilk £¬ÎÄ¿Æ˶ʿ £¬¼ÓÀû¸£ÄáÑÇÖÝÊ¥ºÉÎ÷EcoNugenics¹«Ë¾Ñо¿¿ª·¢²¿Ö÷ÈΡ£ Isaac Eliaz £¬Ò½Ñ§²©Ê¿&ÎÄ¿Æ˶ʿ £¬¼ÓÀû¸£ÄáÑÇÈûÍß˹Íв¨¶ûÒ½ÁÆ¿µ¸´ÖÐÐÄҽѧÖ÷ÈΡ£

     

    ÕªÒª

        Ç¦ÊÇÒ»ÖÖÎÞ´¦²»ÔڵĽðÊô¡£Ëü·ºÆðÔÚÎÒÃǵÄÇé¿öÖÐ £¬ÓÐһЩÇøÓò±ÈÊÀ½çÉÏÆäËû¹ú¼Ò¾ßÓиü¸ßµÄǦˮƽ¡£Ç¦Öж¾ÊÇÓ°Ïìµ±½ñº¢×ÓÉú´æµÄºÜÊÇÖØÒªµÄÂýÐÔÇé¿ö¼²²¡¡£¾¡¹ÜÒ²×öÁËÐí¶àŬÁ¦È¥¿ØÖÆËü £¬Ç¦Öж¾µÄÇé¿öÏÂÈÔÈ»»á·ºÆðÔÚÊÀ½ç¸÷µØ £¬ÌرðÊÇÔÚÉú³¤Öйú¼Ò¡£

        ÔÚÓ×С»úÌåÄÚ £¬ÏÕЩûÓÐϵͳÄܶÔǦ¶¾ÐÔ´øÀ´µÄÓ°ÏìÃâÒß¡£Ç¦ÈÅÂÒ¶àÖÖøϵͳ¡£ÔÚÉíÌå·¢ÓýÖÐ×îÁîÈ˹Ø×¢µÄ²¿·ÖÊÇÄÔ¡£ÔÚÕâ¸öÒªº¦Ê±ÆÚËùÔâÊܵÄÆÆ»µºÜ¿ÉÄÜÓоÃÔ¶µÄÓ°Ïì¡£ÔçÆÚ¶Ô´óÄÔµÄǦ¶¾ÐÔÓ°Ïì»áÑÓÐøµ½ÇàÉÙÄêÒÔ¼°Ö®ºóµÄÉú»îÖС£

         ºÜÊǵÍˮƽµÄǦ¶¾ÐԾͻáÏÔÖøËðÉË´óÄÔ £¬¹Å°åµÄòüºÏÒ½ÁƲ¢²»¿É¸Ä±äÕâÖÖÓ°Ï졣ǦÖж¾»áÔÚÐí¶à·½ÃæÓ°Ïì´óÄÔ £¬´Ó¶øµ¼ÖÂÑÓ³Ù»òÄæתµÄÉú³¤ £¬ÓÀ¾ÃѧϰÕÏ°­ £¬³é´¤ £¬»èØÊ £¬ÉõÖÁËÀÍöµÈ½á¹û¡£ÔÚÃÀ¹ú £¬Ç¦Öж¾ÊǶùͯ×î³£¼ûµÄÇé¿ö¼²²¡¡£Ç¦Öж¾µÄ±¬·¢ÔÚÒ»¶¨Ë®Æ½ÉÏÊܾ­¼Ã×´¿ö £¬Ìض¨ÉçÇøµÄÈË¿Ú¹æÄ£ £¬ÖÖ×å £¬ºÍËù¾ÓסµØÊǷǵÄÓ°Ïì¡£µ«Ç¦Öж¾¿É±¬·¢ÔÚÈκÎÒ»¸öÉç»á £¬½öƵÂʲî±ð°ÕÁË¡£

          ¾Ý±¨µÀ £¬Ç¦Öж¾ÒѾ­·ºÆðÔÚµØÇòÉÏÏÕЩÿһ¸ö¹ú¼Ò¡£1996ÄêµÄÒ»·Ý±¨¸æ·¢Ã÷¾ÓסÔÚÖйú¹¤ÒµºÍ½»Í¨Ã¦ÂµÇøµÄº¢×Óƽ¾ùѪǦˮƽΪ21.8£¨BPB£©ÖÁ67.9΢¿Ë/·ÖÉý¡£ÑªÇ¦ÖµµÄ°Ù·Ö±È¶¼ÔÚ10΢¿Ë/·ÖÉýÒÔÉÏ £¬ÕâÊÇÔÚ¶ùͯǦÖж¾µÄãÐÖµ £¬½éÓÚ64.9£¥ÖÁ99.5£¥¡£ÉõÖÁÔ¼50£¥¡°Î´Ç¦Ì»Â¶¡±µÄº¢×ÓѪǦֵҲÁè¼Ý10΢¿Ë/ ·ÖÉý¡£µÍˮƽµÄǦ̻¶ £¬ÖÇÉ̵ĵ×Ï £¬Éñ¾­µÄ·¢ÓýÒÔ¼°ÉíÌåµÄÉú³¤¼äµÄÏà¹ØÐÔÎÞÒ»ÀýÍâÓÐן߶ÈÒ»ÖÂÐÔ¡£

         ³ÉÄêÈËǦÖж¾Í¨³£ÊÇÒòΪְҵÐÔµÄ̻¶¡£×î½üÔÚÖйúҽѧÎÄÏ×ÉϵÄһƪÎÄÕÂÐû²¼ÁËÔÚ1990ÄêºÍ2005Äê¼äÖйúÊÇÇ鳡ºÏǦ̻¶ˮƽ¼°Ç¦Öж¾µÄ×ܽᱨ¸æ¡£±¨µÀÖÐ×÷Õß·¢Ã÷53.7£¥µÄƽ¾ùÖµ¶¼¸ßÓÚÈ«¹ú****µÄְҵ̻¶ˮƽ¡£

         ÏÖÓеÄòüºÏ¼Áͨ³£»áÓÐÃ÷ÏԵĸ±×÷Óà £¬»áͬÑùòüºÏÈËÌåËùÐè¿óÎïÖÊ £¬²¢ÇÒÍùÍùÊǾ²Âö¸øÒ©ËùÒÔÐèÒªÒ½ÁƼ໤ £¬ÇÒͨ³£ÓÃÓÚ¶ùͯ²»Äþ¾²¡£Ð¡·Ö×Ó¸ÌéÙ¹û½º£¨MCP£©ÊDZê×¼¸ÌéÙ¹û½º´¿»¯µÄÉí·Ö £¬¹Ù·½È·ÈÏΪÄþ¾²µÄ²úÆ·£¨GRAS£©¡£ Ð¡·Ö×Ó¸ÌéÙ¹û½º±»ÈÏΪ¸ú¸ÌéÙ¹û½º¾ßÓÐÏàͬˮƽµÄÄþ¾²Ë®Æ½ £¬ÊÇÒѱ»ÈϿɵÄʳƷÌí¼Ó¼Á¡£

         MCPÊÇÒ»ÖÖ´Ó¸ÌéÙÀàË®¹û¹ûƤÖÐÌáÈ¡µÄÉÅʳÔö²¹¼Á¡£¸ÌéÙ¹û½ºÊÇÒ»ÖÖÅÓ´óµÄ¶àÌÇË®ÈÜÐÔÏËά¡£ D-°ëÈéÌÇÈ©ËáÊǹû½ºµÄÖ÷Òªµ¥ÌÇ £¬µ«ÖÐÐÔÌÇÒ²±£´æ¡£D-°ëÈéÌÇÈ©Ëá²Ð»ùͨ¹ý¦Á-1,4ÌÇÜÕ¼üÁ¬½ÓÔÚÒ»Æð¡£Î´¸ÄÐÔ¹û½ºÊÇÒ»ÖÖ²»Ò×Ïû»¯µÄ¶àÌÇ £¬ÊÇÒ»ÖÖÓн»²æÁ´µÄ¾ÛºÏÎï¡£±¾ÊµÑéÖÐʹÓõÄС·Ö×Ó¹û½ºÊÇͨ¹ýÉúÎïøºÍ¸Ä±äPHÖµ £¬°Ñ¸ÌéÙ¹û½ºÆÊÎöΪ¶ÌÁ´ºÍÉÙ·ÖÖ§µÄ·Ö×ӽṹ¡£½ÏµÍ·Ö×ÓÁ¿Ê¹MCP¿ÉÒÔ±»ÎüÊÕµ½ÑªÒºÖÐ £¬½µµÍµÄõ¥»¯¶ÈʹMCP¸üÒ×½áºÏÑôÀë×Ó¡£ MCPÒÖÖÆ°©Ï¸°ûתÒƺͽµµÍÖ×ÁöµÄÉú³¤ºÍÉú³¤µÄЧ¹ûÒÑΪÈËÊìÖª £¬Í¬Ê±Ò²ÓнµµÍµ¨¹Ì´¼ºÍ´Ì¼¤ÃâÒßϵͳµÄ×÷Óá£ÖµµÃ×¢ÒâµÄÊÇ £¬MCPÖ»½áºÏºÍ´ÙÅÅÓж¾ÖؽðÊô £¬Í¬Ê±²»×ÌÈŽ¡¿µÈËÌåËù±ØÐëµÄ¿óÎïÖÊ¡£MCP±»Ö¤Ã÷¾ßÓÐòüºÏÖؽðÊôµÄ****½á¹¹¡£Ëüº¬Ô¼10£¥µÄÊóÀîÌÇII £¬ÕâÄܽáºÏÖؽðÊôºÍ²»ÐèÒªµÄ¿óÎïÖÊÑôÀë×Ó¡£ËüÒ²ÏÔʾ³öÄÜÔÚ³¤Ê±¼äʹÓúó¼õÉÙÉíÌåÖй¯ÔªËصĵ£¸º¡£

         ×î½üµÄÁÙ´²Êý¾Ý±êÃ÷ £¬MCP×÷ΪһÖÖÖؽðÊôòüºÏ¼Á¿É·¢»ÓÖØÒªµÄÖÎÁÆ×÷Óᣰ©Ö¢»¼ÕßÌåÄÚÖؽðÊôµÄ¸ººÉÒ²ÒýÆðÁ˹㷺µÄ¹Ø×¢ £¬°ÑMCPÓÃÓÚ¼õÇáÖؽðÊô¸ººÉ²¢ÒÖÖÆÖ×ÁöÀ©É¢µÄË«ÖØ×÷ÓÃÊÇÒ»¸öÖØÒªµÄÁÙ´²Ó¦Óá£ÖؽðÊô¡¢Æձ鱣´æµÄÇé¿ö¶¾ÎïºÍÒìÔ´´Æ¼¤ËØ £¬Í¨¹ýDNAËðÉË £¬¼¤Ëص÷ÖÆ £¬ÃâÒßÒÖÖÆ £¬Ñõ»¯Ó¦¼¤ºÍ³¬Ñ×Ö¢×é³ÉÁ˶ÔÉíÌå¾Þ´óµÄË𺦡£ËüÃÇÊÇÔÚÐí¶à°©Ö¢ÖÐÊܵ½Ìرð¹Ø×¢µÄ £¬°üÀ¨Ç°ÁÐÏÙ°©ºÍÈéÏÙ°©¡£MCP°¸ÀýÑо¿ºÍÊÔµãÁÙ´²ÊÔÑ鶼Ìá³ö £¬ºã¾ÃʹÓÃκ͵ÄòüºÏ¼Á £¬ÈçMCP £¬¿ÉÒÔÓÐЧµØ½µµÍÉíÌåÖеÄÖؽðÊôµ£¸º¡£ MCPÔÚÏÖÓлù´¡ÉÏÈ¥³ýÖؽðÊôºÍÇé¿ö¶¾ËصÄÄÜÁ¦ÔÚÁÙ´²ÉÏÓкܴóµÄÒæ´¦¡£

         ÔÚÒ»¸öÊÔµãÁÙ´²ÊÔÑéÖÐ £¬»¼Õß·þÓÃMCPºó·¢Ã÷ÄòÒºÖÐÔö¼ÓÁËÖؽðÊôº¬Á¿ £¬ÈçǦ £¬¹¯ £¬ïÓ £¬Éé¡£¼ÓÈëÕßÁ¬Ðø5Ìì·þÓÃÿÌì15¿ËMCP £¬µÚ6Ìì·þÓÃ20¿Ë¡£±È½ÏµÚÒ»ÌìºÍµÚÁùÌì24СʱÄòÑù»ùÏ߶ÁÊý·¢Ã÷ £¬MCPκ͵ÄÌìÐÔÊÇ¿ÉÒÔÄþ¾²òüºÏ £¬ÎÞ¸±×÷Óõġ£ÔÚÔçÆÚµÄÑо¿ÖÐ £¬GralakµÈÈËÑо¿Á˸ÌéÙ¹û½º¶ÔСÊóÌåÄÚ¸Æ £¬Ã¾ £¬Ìú £¬Ð¿ £¬ÃÌ £¬Í­ÎüÊÕµÄÓ°Ïì¡£ÆäËû¿ÉÈÜÐԺͲ»ÈÜÐÔÏËάÔö¼ÓÁË·à±ãÖÐÖؽðÊôµÄÅÅй £¬µ«½µµÍÁ˸Æ £¬Ã¾ £¬Ìú £¬ÃÌ £¬Ð¿ £¬ºÍÍ­µÄÎüÊÕ £¬¿ÉÊǸ̽۹û½º¾Í²»»áÓ°ÏìÕâЩÓÐÒæÔªËØ¡£Òò´Ë £¬MCPÊÇÒ»ÖÖÑ¡ÔñÐÔòüºÏ¼Á £¬Äܹ»Ôö¼ÓÄòÒºÖÐÖؽðÊôµÄÅÅй £¬µ«²»¼õÉÙÆäËüÈËÌå±ØÐë¿óÎïÖÊ¡£

         ÔÚÁíÒ»¸öÊÔµãÁÙ´²ÊÔÑéÖÐ £¬ÊÓ²ìÁ˺ã¾Ã·þÓÃMCP¶ÔÎå¸öÑо¿¹¤¾ßÌåÄÚ¹¯º¬Á¿µÄÓ°Ïì¡£½«250ºÁ¿Ë2,3-¶þÛÏ»ù-1-±û»ÇËᣨDMPS£©¾²Âö×¢Éäºó £¬ÊÕ¼¯6СʱÄÚµÄÄòÒº £¬ÒÔȨºâ¼ÓÈëÕß»ùÏßÉíÌ幯µ£¸º¡£È»ºóMCPÊ©ÓÃ15¿Ë/ÌìµÄ¼ÁÁ¿¡£Ô¼4ÖÁ10¸öÔºóÔÙ´ÎÕÉÁ¿ÉíÌ幯µ£¸º £¬·¢Ã÷ËùÓÐÊÜÊÔÕß¹¯º¬Á¿Æ½¾ù½µµÍ52΢¿Ë/¿Ë¼¡ËáôûÖÁ16΢¿Ë/¿Ë¼¡Ëáôû¡£Ñо¿¼ÓÈëÕßÌåÄÚ¹¯Ë®Æ½Ï½µÁË69£¥£¨P = 0.03£©¡£

        MCPÔÚ2Àý³ÉÈËÁÙ´²ÊÔÑéÖб¬·¢ÁËÁîÈ˹ÄÎèµÄ½á¹û £¬ËüÔö¼ÓÅÅйÖеÄÖؽðÊôº¬Á¿ £¬¼õÉÙÌåÄÚÓж¾½ðÊô¡£ÕâÏîÁÙ´²ÊÔÑéÆÀ¹ÀÁËMCP¶Ô¼õÉÙ¶ùͯǦ¶¾ÐÔµÄÓÐЧÐÔ¡£¿¼Âǵ½ÔÚÖйú¶¼»á/¹¤Òµ»¯µØÇøǦ¶¾ÐÔÒýÆðµÄ¹«¹²½¡¿µÎ£»ú £¬Ñо¿¹¤¾ßÊÇÆæÌصġ£ÕâƪÎÄÕÂÖÐÎÒÃÇ×ܽáÁ˽«MCP×÷ΪΨһòüºÏ¼ÁºÍÁÆ·¨ £¬Ç¦º¬Á¿ÔÚ5ÖÁ12Ë껼¶ùѪҺÄڵļõÉÙºÍÄòÒºÖеÄÔö¼Ó¡£

     

    ÖÊÁϺÍÒªÁì

         Ñо¿ÔÚÖйúº¼ÖݵÄÕã½­´óѧ¶ùͯҽԺ½øÐС£ÕâÏîÑо¿ÕÐļÁËÆßÃû²¡ÈË¡£ËùÓл¼Õß¾ùÇкÏѪǦŨ¶È>20΢¿Ë/·ÖÉýµÄ×ʸñ±ê×¼ £¬ÇÒ¼ÓÈëÑо¿Ç°µÄ3¸öÔÂÄÚûÓнøÐйýòüºÏºÍ/»ò½â¶¾ÖÎÁÆ¡£Ã¿¸öº¢×ÓµÄâïÊÑ»ò¼à»¤È˼ÓÈëÕâ¸ö¿ª·Å±ê¼ÇµÄÁÙ´²ÊÔÑéÇ°¾ùÐèҪǩÊðÖªÇéͬÒâÊé¡£

         »¼Õß½ÓÊÜÿÌì·þÓÃ15¿ËMCP £¬Ã¿´Î5¿ËÒ»ÈÕÈý´Î¡£ÔÚÑо¿¿ªÊ¼Ç°3¸öÔÂÒÔ¼°Ñо¿Àú³ÌÖÐûÓÐʹÓÃÆäËûµÄòüºÏ»ò½â¶¾¼Á¡£

         ´Ó¿ªÊ¼Ê¹ÓÃMCPÇ°µÄµÚ0Ìì £¬Ö®ºóÿÖÜÕÉÁ¿Ö±µ½»¼Õß³öÔº £¬ÒÔʯī¯ԭ×ÓÎüÊÕ¹âÆ×·¨£¨GFAAS£©¶Ô»¼ÕßµÄѪǦŨ¶ÈºÍ24СʱÄòǦÅÅй½øÐвⶨ¡£2ÖܺóÁ½Î»²¡È˳öÔº £¬3Öܺó3¸ö £¬4ÖܺóÁ½¸ö £¬ËûÃǵÄѪǦˮƽϽµµ½Á˵ÍÓÚ20΢¿Ë/·ÖÉýµÄ±ê×¼¡£

         Àú³ÌÖÐÆÀ¹ÀÁË»¼ÕßÔÚÖÎÁÆÖб¬·¢µÄÖ¢×´ £¬°üÀ¨¶ñ»¯»ò¸ÄÉÆÒÑÓеÄÖ¢×´ £¬ÈκÎеÄÖ¢×´ £¬MCPDZÔڵĸ±×÷Óà £¬ÈçÍ·Í´ £¬¸¹Ðº £¬»ØÁ÷»ò賦µÀÎÉÂÒ £¬Ðļ £¬ÌåÒºäóÁôµÈ¡£½ÓÄÉÁËÒ»°ãѪҺÆÊÎö¶Ô²»Á¼·´Ó¦½øÐÐÁ˼à¿Ø £¬Î´·ºÆðÒì³£½á¹û¡£ Æ¾¾Ý²¡Çé £¬±¾Ñо¿µÄ¶ùͯûÓÐÈκÎÌØÊâµÄÒûʳ¡£

    ÓøßЧÒõÀë×Ó½»»»É«Æ×·¨ºÍÂö³å°²Åà¼ì²â·¨£¨HPAEC£­PAD£©¼×´¼ÆÊÎöºó½øÐÐMCPµÄµ¥ÌÇÆÊÎö¡£Ê¹ÓÃA´÷°²DX-500ϵͳ£¨´÷°²¹«Ë¾ £¬É£Äáά¶û £¬¼ÓÖÝ£© £¬°üÀ¨Ò»¸ö0.5ºÁÉý/·ÖÖÓ²Ù×÷µÄCarboPac PA-20Öù¡£ÓÃ14mMµÄÇâÑõ»¯ÄÆ£¨NaOH£©Á÷¶¯ÏàµÈŨ¶È´¦Àí13·ÖÖÓ £¬È»ºó½«100mMÇâÑõ»¯ÄƺÍ0-120 mMÒÒËáÄÆ£¨CH3COONa£©Ìݶȴ¦Àí30·ÖÖÓ £¬½«ÖÐÐÔºÍËáÐÔµ¥ÌÇÊèÉ¢¡£ÔÚÏÂÒ»´Î×¢ÉäÇ°40·ÖÖÓ½«Á÷¶¯ÏàÒÆ»Ø14ºÁÃ×ÇâÑõ»¯ÄÆ¡£ÆäËûÇé¿ö֮ǰÒѾ­±¨µÀ¡£

     

    ½áÂÛ

        ±í1×ܽáÁËʹÓÃMCPÇ°ºó £¬ÑªÇ¦Å¨¶ÈµÄ±ä¸ï¡£ËùÓÐ7¸öÊÜÊÔÕßѪҺÖÐǦº¬Á¿ÏÔÖøϽµ¡£Í¼1ÏÔʾ³öÁË´ÓµÚ0Ì쿪ʼ¼°ÔÚÖÎÁÆÀú³ÌÖвâµÃµÄ·åֵѪǦŨ¶ÈµÄ±ä¸ï¡£½ÓÄÉÅä¶ÔÑù±¾Æ½¾ùÖµµÄͳ¼ÆÆÊÎö½á¹ûÊ®·ÖÏÔÖø£¨P = .0016£©¡£±í2×ܽáÁËÖÎÁÆÇ°ºÍ·åֵʱ»¼Õß24Сʱ×ÜÄòÅÅйǦº¬Á¿µÄ±ä¸ï¡£Í¼2×ܽáÁ˵Ú0ÌìºÍÖÎÁÆÀú³ÌÖзåֵʱ»¼Õß24Сʱ×ÜÄòÅÅйÖÐǦº¬Á¿µÄ±ä¸ï¡£½ÓÄÉÅä¶ÔÑù±¾Æ½¾ùÖµµÄͳ¼ÆÆÊÎö½á¹ûºÜÊÇÏÔ×Å£¨P=0.0007£©¡£¾Ý±¨¸æ £¬Ã»Óб¬·¢²»Á¼·´Ó¦¡£ÁíÓÐ3¸ö¶ùͯÄêÁäÔÚÎåËêÒÔÏ£¨2.5µ½3.5Ëê¼ä£©Ò²Ê¹ÓÃÁËMCP½øÐÐÖÎÁÆ £¬µ«ÒòΪ²»ÇкÏÄêÁä±ê׼佫½á¹ûÊÕ¼ÔÚ±¾´ÎʵÑéÄÚ¡£ËûÃÇҲȡµÃÁËÀàËƵÄʵÑé½á¹û £¬ÇÒÎÞÈκβ»Á¼·´Ó¦¡£Í¼3ÏÔʾÁËÊÜÊÔÕß×é24СʱѪҺºÍÄòÒºÖÐǦº¬Á¿µÄƽ¾ù°Ù·Ö±È±ä¸ï¡£

         Í¼4ÏÔʾÁ˵¥ÌÇÆÊÎöÉ«Æ× £¬Õâ±êÃ÷MCPº¬88.2£¥µÄ°ëÈéÌÇÈ©Ëá¡£¾ÍÈç֮ǰÌáµ½µÄ £¬MCPµ¥ÌÇÓÐ׎µµÍµÄ·Ö×ÓÁ¿ £¬ÍÑÖ§ £¬¸üµÍµÄõ¥»¯¶È£¨3.8£¥£© £¬µÍÊóÀîII£¨10£¥£©¡£

    918²©ÌìÌÃ(ÖйúÇø)Æì½¢Ìü

     918²©ÌìÌÃ(ÖйúÇø)Æì½¢Ìü

    918²©ÌìÌÃ(ÖйúÇø)Æì½¢Ìü

    918²©ÌìÌÃ(ÖйúÇø)Æì½¢Ìü

     

    ÌÖÂÛ

         Ò»°ãÈËÌرðÊǶùͯµÄǦÖж¾ÊÇÒ»¸öÒýÆð¹ã·º¹Ø×¢µÄÈ«Çò½¡¿µÒéÌâ £¬Ëü»á¶ÔÉíÌå¶à¸öϵͳÔì³É²î±ðˮƽµÄ½¡¿µÎÊÌâ¡£±¾ÁÙ´²Ñо¿µÄÄ¿µÄÊÇÆÀ¹ÀMCP¹ØÓÚǦ¶¾»¼¶ù¼õÉÙǦ¶¾ÐÔµÄÓÐЧÐÔ¡£ËùÓвâÊÔµÄÊÜÊÔÕßÄòÒºÖÐǦº¬Á¿¶¼ÏÔÖøÔö¼Ó £¬Í¬Ê±ÑªÒºÖÐǦº¬Á¿ÏÔÖø½µµÍ¡£¾Ý±¨¸æ £¬Ã»Óб¬·¢¸±×÷Ó᣸ýá¹ûÇå³þµØÖ¤Ã÷ÁËMCP×÷ΪǦòüºÏ¼ÁµÄÓÐЧÐÔºÍÄþ¾²ÐÔ¡£

          ²»ÐÒµÄÊÇ £¬ÕâЩº¢×ÓÔÚÒªº¦µÄÉú³¤Ê±ÆÚÖ»ÄÜÓֻص½ºã¾ÃǦ̻¶µÄÇé¿öÀï £¬µ¼Ö½øÒ»²½µÄǦ¶¾ £¬Ôì³ÉÁËËûÃÇÖÕÉíµÄÉ˺¦¡£Ç¦Ì»Â¶¿Éµ¼ÖÂÈ«ÇòÊý°ÙÍò¶ùͯµÄÁ¬Ðø½¡¿µÎ£º¦¡£ÔÚ½â¾öÕâ¸öÎÊÌâµÄʱºò £¬ÎÒÃÇÐèҪѰÕÒÒ»ÖÖÄþ¾²µÄǦÒƳý¼Á £¬ÔÚÒƳýÌåÄÚÏÖÓÐǦ¶¾ËصÄͬʱ±ÜÃâÓÉÓÚÁ¬Ðø½Ó´¥µ¼ÖµÄǦÎüÊÕ¡£Ä¿Ç° £¬Ö÷ÒªÓÃÓÚìî³ýǦ¶¾ÐÔµÄÊÔ¼ÁΪÒÒ¶þ°·ËÄÒÒËᣨEDTA£© £¬ËüÐè¾²Âö×¢Éä £¬±¾Ç®¸ß £¬ÇÒÓÐDZÔڵĸ±×÷Óá£EDTA £¬ÒÔ¼°ÆäËûÊÔ¼Á £¬ÈçÄÚÏûÐý-2,3-¶þÛÏ»ùçúçêËᣨDMSA£©ºÍDMPS £¬»áÏûºÄÈËÌåÄÚ±ØÐë¿óÎïÖʲ¢¿ÉÄܻᵼÖÂÖؽðÊôµÄÖØзÖÅÉ £¬Ê¹ËüÃÇÔÚÖØÒªÆ÷¹Ù¼¯ÖÐ £¬ºÃ±È´óÄÔ¡£Òò´ËÕâЩҩÎï²»ÊʺÏÓÚ¼ÌÐøʹÓá£Ñ°ÕÒÒ»ÖÖÄþ¾²ºÍÄܹ»ºã¾ÃʹÓõÄÑ¡ÔñÐÔòüºÏ¼ÁÊ®·ÖÐëÒª¡£ºã¾Ã·þÓÃMCP²»»áÔì³ÉÈκθ±×÷ÓÃÒѱ»¶àÀý֤ʵ £¬ÈçÓÃÓÚ»¼Ç°ÁÐÏÙ°©µÄ³ÉÈË£¨12¸öÔ£© £¬ÓÃÓÚ¼õÉÙ³ÉÄêÈËÌåÄÚ¹¯µ£¸º£¨10¸öÔ£© £¬ÒÔ¼°Ò»ÏîʹÓÃMCPµÄ²¡Àý±¨¸æ£¨12¸öÔ£©¡£

         ×÷Ϊһ¸öϵͳÐÔµÄòüºÏ¼Á £¬MCP¾ßÓнµµÍÈËÌåÌåÄÚÖؽðÊôµ£¸º²¢²»±¬·¢¸±×÷ÓõÄÄÜÁ¦¡£MCPµÄµÍõ¥»¯¶ÈͬÐÍ°ëÈéÌÇÈ©ËáºÍÊóÀîII ½á¹¹Öк¬Óи»ºñµÄ×ÔÓÉôÈ»ù £¬ÊÇÀíÏëµÄǦµÈÑôÀë×ÓµÄòüºÏ¼Á¡£ÎÒÃÇÈÏΪ £¬ÔÚMCPÖеÄÊóÀîIIÔÚòüºÏÖؽðÊôºÍÈËÌå·Ç±ØÐë¿óÎïÑôÀë×Óʱ¾ßÓÐÑ¡ÔñÐÔ¡£ÏÔÈ» £¬µÍ·Ö×ÓÁ¿ºÍÊóÀî½á¹¹ÔÊÐíMCPͨ¹ý賦ÉãÈ¡ºóÖ±½Ó½«ÑªÒºÖÐÖؽðÊôòüºÏ £¬Ö®ºóËæÄòÒºÅųö¡£ÎÒÃÇÒѾ­½«MCP×÷ΪÖؽðÊôòüºÏ¼ÁÓÃÓÚ½¡¿µÈËȺµÄÁÙ´²ÊÔÑéÖÐ £¬ÂýÐÔ¼²²¡µÄ³ÉÈËÉíÉÏ £¬ÖؽðÊô³¬±êÈËȺÉíÉÏ £¬ÒÔ¼°´Ë´ÎÒ½Ôº¼à²âµÄºã¾ÃǦ̻¶µ¼ÖÂǦÖж¾µÄº¢×ÓÉíÉÏ¡£ Èô½«MCPÓë¸ÄÐÔÔåËáÑνáºÏ £¬¿ÉÒÔÔöÇ¿òüÏàÖúÓûòÒÔ¸üµÍ¼ÁÁ¿ÊµÏÖ¡£ÕâÀï¸ø³öµÄ½á¹ûÏÔʾMCP¿ÉÒÔ×÷ΪһÖÖÓÐЧµÄòüºÏ¼Á £¬µ«ÈÔÐè¸ü¶àµÄÁÙ´²Ñо¿ÒÔÈ·ÈÏÎÒÃǵķ¢Ã÷ÒÔ¼°½øÒ»²½ÓÅ»¯MCP×Ô¼º»ò½áºÏ¸ÄÐÔÔåËáÑεĹ㷺ӦÓà £¬ÓÈÆäÊÇÕë¶Ô½â¾öºã¾Ã̻¶ÔÚÇé¿ö¶¾ËØϺ¢×ÓµÄÎÊÌâ¡£

     

    ÖÂл

    ×÷ÕßллMadhav Yadav ºÍAndre White¸øÓèµÄ¼¼ÊõÖ§³Ö¡£

     

    ²Î¿¼ÎÄÏ×

     

    1. Moore MR, McIntosh MJ, Bushnell IW. The neurotoxicology of lead. Neurotoxicology. 1986;7(2):541-556.

     

    2. Lanphear BP, Hornung R, Khoury J, et al. Low-level environmental lead exposure and children¡¯s intellectual function: an international pooled analysis. Environ Health Perspect. 2005;113(7):894-899.

     

    3. Järup L. Hazards of heavy metal contamination. Br Med Bull. 2003;68:167-182.

     

    4. Rosen JF. Adverse health effects of lead at low exposure levels: trends in the management of childhood lead poisoning. Toxicology. 1995;97(1-3):11-17.

     

    5. Mendelsohn AL, Dreyer BP, Fierman AH, et al. Low-level lead exposure and cognitive development in early childhood. J Dev Behav Pediatr. 1999;20(6):425-431.

    6. Shen X, Rosen JF, Guo D, Wu S. Childhood lead poisoning in China. Sci Total Environ. 1996;181(2):101-109.

     

    7. Shen X, Wu S, Yan C. Impacts of low-level lead exposure on development of children: recent studies in China. Clin Chim Acta. 2001;313(1-2):217-220.

    8. Ye X, Wong O. Lead exposure, lead poisoning, and lead regulatory standards in China, 1990-2005. Regul Toxicol Pharmacol. 2006;46(2):157-162.

    9. Modified citrus pectin monograph. Altern Med Rev. 2000;5(6):573-575.

     

    10. Pienta KJ, Naik H, Akhtar A, et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst. 1995;87(5):348-353.

     

    11. Hayashi A, Gillen AC, Lott JR. Effects of daily oral administration of quercetin chalcone and modified citrus pectin on implanted colon-25 tumor growth in Balb-c mice. Altern Med Rev. 2000;5(6):546-552.

     

    12. Guess BW, Scholz MC, Strum SB, Lam RY, Johnson HJ, Jennrich RI. Modified citrus pec-tin (MCP) increases the prostate-specific antigen doubling time in men with prostate can-cer: a phase II pilot study. Prostate Cancer Prostatic Dis. 2003;6(4):301-304.

    13. Hexeberg S, Hexeberg E, Willumsen N, Berge RK. A study on lipid metabolism in heart and liver of cholesterol- and pectin-fed rats. Br J Nutr. 1994;71(2):181-192.

     

    14. Zhu HG, Zollner TM, Klein-Franke A, Anderer FA. Enhancement of MHC-unrestricted cytotoxic activity of human CD56+ CD3- natural killer (NK) cells and CD3+ T cells by rhamnogalacturonan: target cell specificity and activity against NK-insensitive targets. J Cancer Res Clin Oncol. 1994;120(7):383-388.

     

    15. Eliaz I, Hotchkiss AT, Fishman ML, Rode D. The effect of modified citrus pectin on uri-nary excretion of toxic elements. Phytother Res. 2006;20(10):859-864.

     

    16. Eliaz I, Gaurdino J, Hughes K. The health benefits of modified citrus pectin. In: Patil BS, Turner ND, Miller EG, Brodbelt JS, eds. Potential Health Benefits of Citrus. ACS Symposium Series 936. Oxford, UK: Oxford University Press; 2006:199-210.

    17. Eliaz I, Weil E, Wilk B. Integrative medicine and the role of modified citrus pectin/alg-inates in heavy metal chelation and detoxification¡ªfive case reports. Forsch Komplement Med (2006). 2007;14(6):358-364.

     

    17. Gralak MA. Leontowicz M, Morawiec M, Bartnikowska E, Kulasek GW. Comparison of the influence of dietary fibre sources with different proportions of soluble and insoluble fibre on Ca, Mg, Fe, Zn, Mn and Cu apparent absorption in rats. Arch Tiernahr. 1996;49(4):293-299.

     

    18. Manderson K, Pinart M, Tuohy KM, et al. In vitro determination of prebiotic properties of oligosaccharides derived from orange juice manufacturing by-product stream. Appl Environ Microbial. 2005;71(12):8383-8389.

     

    19. Kohn R. Binding of toxic cations to pectin, its oligomeric fragments and plant tissues. Carbohydr Polym. 1982;2(4):273-275.

     

    20. O¡¯Neill MA, Warrenfeltz D, Kates K, et al. Rhamnogalacturonan-II, a pectic polysaccha-ride in the walls of growing plant cell, forms a dimer that is covalently cross-linked by borate ester. In vitro conditions for the formation and hydrolysis of the dimer. J Biol Chem. 1996;27(37)1;22923-22930.

  • ÉÏһƪ£ºÔÝÎÞ
    ÏÂһƪ£º
  • ·µ»ØÐÂÎÅÁбí
 

    ÁªÏµ918²«ÌìÌÃ

  • µØµã£ºÕã½­Ê¡áéÖÝÊж«¸Û¾­¼Ã¿ª·¢Çø¶«¸Û4·2ºÅ
  • ÁªÏµµç»°£º0570£­8788056
  • ×ÉѯÈÈÏߣº400-7118-600
  • E-mail£ºzjgykp@163.com

Coptyright © 2018 zjgykp.com All Rights Reserved. °æȨËùÓÐ 918²«ÌìÌà  ¼¼ÊõÖ§³Ö£ºÕã½­Ö¥Â鿪ÃÅ  ÕãICP±¸19048970ºÅ-1|ºǫ́ÖÎÀí
ÍøÕ¾µØͼ
ÓÑÇéÁ´½Ó£ºAGÕæÈ˹ú¼Ê  ½ðÄê»á  918²©ÌìÌà Ôƶ¥¼¯ÍŹÙÍø  ng28ÄϹ¬  J9ÕæÈË  ÈËÉú¾ÍÊDz©  ÄϹ¬28  AGÕæÈ˹ú¼Ê  ¿­·¢k8¹ú¼Ê  Ôƶ¥¹ú¼Ê  ½ñÄê»á  Ç§ÒÚÇòÓѻᠠ8868ÌåÓý¹ÙÍø  918²©ÌìÌÃÏÂÔØ